ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
Drs D. Chen and Yidilisi contributed equally to this work as first authors. Drs D. Chen and Yidilisi contributed equally to this work as first…
Primary percutaneous coronary intervention using a drug-eluting stent (DES) is the reperfusion therapy of choice in patients presenting with ST-segment elevation myocardial infarction (STEMI). 1…
AbstractBackgroundMicrovascular resistance reserve (MRR) can characterize coronary microvascular dysfunction (CMD); however, its prognostic impact in ST-segment elevation myocardial infarction (STE…
AbstractBackgroundThe role of quantitative flow ratio (QFR) in the treatment of nonculprit vessels of patients with myocardial infarction (MI) is a topic of ongoing discussion.ObjectivesThis…
ABSTRACTBackgroundTranscatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis is technically challenging and is burdened by an increased risk of paravalvular…
New research presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12–15 May), reveals the anti-inflammatory power of moderate-to-vigorous aerobic exercise in…
As part of their sustainable development goals, the United Nations (UN) aims to achieve a one-third reduction in premature mortality attributed to non-comm
🙏Srimad Bhagavad Gita Chapter 14 Verse 16🙏The feeling for doing the work makes the work Satvik, Rajasik or Tamasik.🙏Hare Krishna🙏
AbstractBackground and Aims. Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant pro